Targeting Multiple Myeloma

Learn how rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma

[wpbb post:title]
Andrea Schmidts, Postdoctoral Research Fellow, MD Cellular Immunotherapy Program, MGH Cancer Center and Harvard Medical School
  • Discover how a trimeric extracellular moiety of APRIL has enhanced binding to BCMA and TACI compared with monomeric APRIL when incorporated into a CAR

  • Explore why trimeric APRIL-based CAR are efficient against BCMA-negative multiple myeloma

  • Learn why T cells transduced with a trimeric APRIL-based CAR are a promising approach for the treatment of multiple myeloma

2020-09-21T01:38:32-04:00